I would think you'd buy on the dips rather than sell. Water the flowers and pick the weeds.
I'm holding though, might be biased
Printable View
I would think you'd buy on the dips rather than sell. Water the flowers and pick the weeds.
I'm holding though, might be biased
Seems to blow cytology right out of the water on all counts. IF it becomes part of the gold standard and in the clinical pathway I'm seriously considering that Johnnythe Horse's Intrinsic Value Chart may become completely out of whack at 2013 .5, 2014 2, 2015 5, 2016 10, 2017 13 % market penetration
If Boston didn’t suit, how about a spot in Chicago, Dallas or Houston ?
http://www.linkedin.com/jobs2/view/1...ublic_seo_page
It's all very well but are they actually making any real progress towards real volume sales?
I have dealt with far too many sales and marketing men who were, at the end of the day, full of nothing but hot air.
The proof of the pudding is in the eating as some ethnic group somewhere used to say. Let us see some sales numbers that at least covers the cost of employing this bunch of people.
Best Wishes
Paper Tiger
MAC - great intelligence.
I've worked in corporate sales, so the words "strategic account manager" mean a couple of things.
1. "Account manager" is someone who is given accounts to look after - e.g., they don't often go out and win the business, they are there to maintain and grow the business of their client. It suggests PEB is confident that they have won the business that the account manager is supposed to maintain.
2. "Strategic" is music to my ears also. Strategic means a client who is big enough to demand extra levels of support. So unlikely that a "strategic account manager" would be tending to smaller urology groups, but more likely to be larger HMOs or a very important vertical market client like the Firefighters or Veterans Affairs.
It sure sounds to me that PEB has won some larger accounts that demand a higher level of service and attention. Sounds good to me.
It does seem to be a more senior position than the Boston Account Executive spot advertised a couple of weeks ago which presumably from the description was one of the nineteen sales territory roles.
I also don’t think it is a coincidence either that two of the largest Medicare regional offices are located in Chicago and Dallas.
http://www.pacificedge.co.nz/assets/...e-13June13.pdf
It’s a five year plan not a five minute plan, all good progress, onward and steadily forward.
Did you mean "this morning a bottle of wine worth in access of $250 turned up on my door step" or was it a cheap bottle on an expensive door step?
It is bargain.
If posters could also not confuse course as in 'of course' with coarse as in 'he was rather a coarse person' that would be good as well.
Best Wishes
Paper Tiger
Isee grape seed is the new answer to all your problems. Does this mean that PEB has been given the pip?
This sounds like somebody chucking rocks in a glasshouse. To gain access to the doorstep the entry fee is in excess of $250.00 but of coarse what do I gno.
Cheers:)
English tutorial for PT. Check out your post #127 on the FPH thread .If posters did not confuse you're and your that would be good.
Cheers :)
That’s looking like a pretty full dance card now, good to see more sales staff more on the road with three venues back to back in March alone now (Brisbane, Florida and Ohio), sure they are just conferences and conventions but it does seem to affirm the ramp up effort and what better exposure to a target market.
http://www.pacificedgedx.com/news-an...dar-of-events/
Looks like a lot of steam is falling out of PEB. Traders trading?
I suspect its because PEB relatively over-valued based on its forward sales trajectory and it has sustained these highs to date due a series of good announcements. As the news flow stagnates it is only logical to expect investors interest to wane.
DISC: Not holding and not saying the company isn't good. I just think its priced to far in advance of itself relative to other biotechs.
Weird how these 'big sellers' are selling more and more, when these good news announcements have de-risked PEB further more, who knows, maybe some of these big sellers are thinking on the lines of whipmoney
Perhaps, Baller, but in my limited experience I have noticed that when someone wants to sell then good news is a good time to do it.. Because there's more volume buying at the current price. If they sold prior to the news then the price would drop quicker and they would get less return.
Your guess is as good as mine though.
Robbo has hit the nail on the head.
If I were a big holder and viewed the stock as currently over-valued then I would look to distribute (sell-down) just after the good news has come out whilst the stock is still bouyant and when there's lots of liquidity on the bid-side.
That way you can exit your position with a decent average sell-price as opposed to eekking out every cent of value and risk not being able to off-load all of your position at a decent price.
Every stock will have traders to a degree but I have to ask... who are these mysterious traders with several hundred thousand shares? I would have always thought that the traders (as a group) are still relatively small in the scheme of things compared to the instos... unless of course theres some sizeable prop trader desks out there trading on leverage (as I know there is in Aussie).
Yes, I figured that out, to get the volume through with a good price, which I stated a few days ago.
However, I don't quite understand, if all these big sellers have been selling since every good announcement from last year, why are they still off loading so many shares? All these 100's of 100k parcels add up to 10's millions and millions. However, if we look it from the opposite perspective, apart from today, all these shares are getting eaten up at a consolidation price around 1.61-1.63, so that's a good sign in itself also maybe? So over-valued or not is hard to say, Bollinger bands are squeezed very tight, and the lower BB if I'm not wrong is at $1.61.
Maybe a few institutions are still re-balancing their portfolios? Or overvalued as whipmoney thinks?
Not too sure, just trying to understand the market.
Also it makes me wonder at the same time, if it is these institutions selling down, why can't they wait a month, 2 months or even 3-4 months? Something like a medicare announcement ( though nothing is 100% certain), but once again, we can never understand why people sell as there are various reasons behind it.
But, for institutions?
Happily holding :D
Just trying to learn and feel for the market more and more!
Pardon me for my essay lol
There have been some decent sized bids as well lately. Perhaps they can see an urgency in the selling and pulled out late today. Who knows, not me but there is still good interest in this stock.
no sweat, the movements are not dramatic, and without news, those unbooked profits burn holes in pockets and weigh on short term nerves.
you are right to say large holders will distribute into good pockets of liquidity. In the NZ market they have little option
Institutions and some of the larger investors who have been in since as far back as 20c often have no choice but to manage their portfolio within strict and quite specific diversification limits and rules.
With a quickly growing stock like Pacific Edge some of them will be shedding shares every now and then as the share price continues to rise and will probably continue to do so as the company grows over the next few years.
My FA suggests PEB is undervalued, and will be even more so should they deliver on ‘the tens of thousands of sales in 2014’ guidance.
The patient investor gets the rewards the twitchy investor just gets to pay brokerage.
Hmmm, haven't run any figures myself, but the question for me is what will we think of a price at $1.60 - $1.65 if PEB signs a large US deal? Depending on how likely you think a deal is, and/or how far away that might be, this may make $1.60 seem cheap or expensive.
Disc - holding tight.
Perhaps they are selling up to buy Genesis.
Now back to my hole.
I look at it this way Longhaul;
If you work from the Harbour Asset Management revenue curve, just simply because it’s a traceable one and is likely representative of present market thinking. It provides for US Cxbladder revenues up to the PEB goal of US$100M in 2018.
A DCF based on this revenue stream, inclusive of gross margin and other information provided by Pacific Edge will provide any competent analyst with a valuation at about present levels. Valuations based on this revenue curve may probably well continue to put a floor under the share price. That floor will continue to rise over time provided PEB deliver with the said revenues as they go.
There are though two additional aspects to consider that should probably further increase the valuation of the stock within 2014;
1. If PEB deliver on their guidance of providing ‘tens of thousands of sales in 2014’ then valuations will increase. Note for instance that the Harbour estimate of NZ$7.5M in 2014 equates to only 13,600 sales. PEB’s 'tens of thousands' guidance now spans a range of between 20,000 to 99,000 sales.
2. The anticipated new product releases planned for 2014 are yet to be adequately valued by most if not all analysts as there is still little accurate information available to do so, although this information may be better provided by PEB upon product release. There are at least two new products to be released in 2014 each with their own additional revenue streams to that above.
Trust this provides one humble analyst's perspective.
regards, Mac
Attachment 5546
If you are looking to top up then wait until it becomes oversold and bounces off support. 150, 138-140, 130 and 120 are the places to watch.
Peb obtains 4.5mill grant from Callaghan Innovation
Callaghan Innovation Growth Grant
10:00am, 27 Feb 2014 | GENERAL
Callaghan Innovation Growth Grant accelerates Cxbladder development
Pacific Edge is delighted to have the support of Callaghan Innovation to further accelerate the development of its molecular cancer detection technology.
Callaghan Innovation has announced a Growth Grant for Pacific Edge that will provide up to $4.5 million spread over three years with additional funding for a further two years available on review.
Pacific Edge Chief Operations Officer Jimmy Suttie says the Government’s Callaghan Innovation fund recognises the ability of the Company to turn scientific discovery into products that bring real benefits for clinicians and patients.
“This funding will provide additional resources to accelerate the development of a range of cancer detection tests, including further non-invasive bladder cancer tests under the brand of Cxbladder. Cxbladderdetect is now available to patients and their clinicians in the USA, New Zealand and Australia. This one-stop shop of products is designed to enhance the clinician’s perspective of the urological tract for patients presenting with symptoms of possible bladder cancer.”
Pacific Edge’s Chief Executive Officer David Darling says the Callaghan Innovation Growth Grant is also recognition for those shareholders who have supported Pacific Edge through the years of research, product development and commercialisation.
“Pacific Edge started out with a mission to make a real difference by finding ways to identify a range of cancers in their early stages when they can be treated with less devastating impact on peoples lives.”
Cxbladder is the first commercial result of that research. Pacific Edge also has patents for diagnostic and prognostic tests for a range of other cancers including colorectal, gastric and melanoma.
The Growth Grant will supplement Pacific Edge’s own research and product development budget and lead to the employment of further research staff at its Dunedin Headquarters and Research Facility.
For more information contact:
Well that’s great news, more seed funding for additional research staff and pipeline products within an innovative R&D facility with a history of commercialising products at a fraction of the cost it would otherwise take abroad.
“Pacific Edge started out with a mission to make a real difference by finding ways to identify a range of cancers in their early stages when they can be treated with less devastating impact on peoples lives.”
Makes it a pleasure to be a PEB shareholder.
Looking at its chart, PEB's previous support at 160c has now become a technical resistance.
Personally, I would only buy again if either:
a) it holds for the day above 160c...or
b) as JTH points out, it falls to test again its confirmed support at 150c (or possibly even lower to around 130cps if next week we see a large drop in US Equity Market Indices).
Crumbs Johnny, it's already undervalued, I'm not sure you'll ever see any of those levels ever again, certainly not on fundamental grounds. Took advantage of the dip back to the MA50 and picked up a few for a family member yesterday.
Today's positive announcement has failed to fire up any significant buying support, whilst the sellers are still ever present - that's bearish.
...for now.
I sold some at $1.63 then more at $1.60, will buy back just before the NZX50 listing regardless of price in hope price will strengthen once in the NZX50. What's the general perception ? will price climb once in NZX50 ? or are those NZX50 fund managers buying now ?
I run two accounts - one as a medium-to-long term investment portfolio (under a friend's name) and the other a short-term trading account (under my name).
It's lucrative and personally more satisfying to trade off both fundamentals and chart technical analysis (TA).
For both portfolios, a stock will qualify for my watch-lists normally by its fundamentals but I will not buy it until the TA lines up -- either when it's oversold (e.g. BRL.nzx), broken through key resistance (e.g. EVN.asx last week) or when dipping on an upward trend-line (e.g. PDN.asx, CDY.asx, etc).
My buying and selling strategies for the two different portfolios are different. Short-term for the trading portfolio when spikes provide me a quick profit (adopting a business mindset); the other medium-to-long term for the investment portfolio, when I will tend to hug a trendline, looking for fundamental shifts in value and/or broader market momentum to trigger a trade.
It's taken a few years to develop the discipline required to manage the two portfolios with different approaches, but now that I have, I can sleep better at night, keep the tax man happy enough come mid-year, and afford the odd luxury for family treats throughout the year. I'm not nearly as wealthy as some posting on ST, but I am able to make a living doing it, and enjoy the challenges it brings along.
But each to his own.
BC
Yes, and dont forget five months ago the share price was $1.00 less than now.
Bobcat sold out at 1.70 or so he informed us and indicated he was waiting for the equity markets to slump which he has again reiterated. This is trader action not long term holder
I started accumulating PEB in late Feb last year. I have not sold any at all. There are enough numbers to make a big difference from here on especially if they ever pay a dividend. Big if I know.
I bought PEB in the low .50's early October (partly due to the positive slant given by posters on this thread, thnx).
My trading action sold it at $1.49 late November (as it approached what was then an earlier resistance).
My investment action sold what was in my investment portfolio at $1.72 mid Jan.
I have not bought since, and am no longer holding.
My strategy is:
Plan A: to wait until after the Equity market correction.
Plan B: if that doesn't happen soon, to buy PEB if and when it tests $1.50 for the third time - for both portfolios but ready to take a quick profit on my trading portfolio following some upside pressure from PEB's NZX50 inclusion.
Would anyone else care to disclose their strategy for this stock? Apart from simply holding and waiting, that is.
Cheers,
BC
Yes, if PEB tests 1.50 before the Equity market correction happens then I will likely buy some.
If the converse is true, I doubt 1.50 will hold, and so will not.
Divine Intervention I would guess.....
I agree Bobcat. Most stocks tend to get upside from NZX50 inclusion, I cant see why PEB wont be any different so I took profits on 25% of my PEB, just in case we see a drop to say $1.50 before inclusion. I will buy back before and if there is a upside after inclusion will probably sell that 25% again, just depends on how steep the upside is. 5% + and I'll sell then wait for a drop. Thats my plan.!
MAC v Bobcat approach different. Here's Mr Buffet's way f describing MACs way of investing/trading
With my two small investments, I thought only of what the properties would produce and cared not at all about their daily valuations. Games are won by players who focus on the playing field – not by those whose eyes are glued to the scoreboard. If you can enjoy Saturdays and Sundays without looking at stock prices, give it a try on weekdays.
Mind you MAC keeps a close eye on price.
Full article
http://www.mauldineconomics.com/outs...te-investments
I know this has been addressed before but what is the timing for NZX50 inclusion?
With PEB's Market Cap being now in excess of $500m and its current sales being less than $1m, I would be cautious about ascribing MAC's investment style to that of the Buffet/Graham Value Investing philosophy.
This is clearly a high-risk growth play and completely out of the realm of the Buffet Methodology.
Each to their own Winner, that’s fair isn’t it, although I find the passion of some in trying to trade a stock like PEB curious. The fundamentals are relatively quantifiable, there is a reasonable floor under the share price and it’s far from being a volatile spec stock with little guidance.
Something that you Traders might be interested in;
As a part of portfolio risk management I calculate twelve month trailing Beta for each holding and for my overall portfolio, it gives some degree at least of correction ride through.
The twelve month trailing S&P500 Beta for PEB is only 0.61, way down there with all those retirement sector stocks. I wish you well if you are waiting for a lot of volatility to occur.
I wasn't implying PEB a Buffett type stock ....just pointing out that Buffett's style is akin to Mac!s the bit about focusing on the field and not the scoreboard.
Talking of Buffett remind me his formula gave a 333 valuation for DIL but as no positive cash flow the same formula doesn't work for PEB
But isn't akin to saying anyone who goes long in a share is behaving like Buffet?
That would make sense given Buffets valuation model isn't geared towards investing in high growth (high risk) companies.Quote:
Talking of Buffett remind me his formula gave a 333 valuation for DIL but as no positive cash flow the same formula doesn't work for PEB
I'm not sure how any simple heuristic model such as the one above could accurately capture the value of a share like DIL or PEB which will have multiple speeds of growth over the next few years. DCF analysis would clearly be a far superior tool.
Personally I agree with your investment approach MAC (albeit I would probably value PEB a lot lower) whereby you invest in the fundamentals and take the techincals with a large grain of salt.
You mention volatility which is interesting because as a fundamental/value investor I actually consider this to be one of the lesser risks of stock investing. Over the long-run the noise will cancel out, yet the real risks always remain, e.g. credit risk (default), political/regulatory risk (e.g. chorus) and various other forms of risk.
Absolutely nice Hancock’s, and I just wonder too if that grant, although not dedicated to Cxcolorectal, may free up some cashflow from the pool to bring the Cxcolorectal launch forward.
An additional $4.5M in the coffers and products on the shelf all good to go and market ready.
Thought that beta number you quoted was a bit awry in light of PEB being up 150% odd last 12 months and markets nowhere near that. Done the calc and it is indeed about 0.61 v S&P500
Different story v home market NZ50 though. If yahoo data is correct it is over 2. (I have known to be wrong). So a high degree of relative 'volatility' v the NZX50 which I would have expected but means nz50 and s&p500 are poles apart. Might look at
Just an interesting insight
Do you use Sharpe Ratio or such things to assess your overall portfolio performance?
Just because the stock jumped 150% that isn't necessarily a sign that it will have a beta in excess of 1 when benchmarking against say the NZX50. Generally the variance/co-variance should be calculated against daily returns (movements) and it would be handy to remember that a large part of PEB's jump took place late in the year.
Given that i'm inherently cognitively lazy and without doing any quant analysis whatsover, logic could suggest that PEB could have a relatively modest beta (less than 1) and yet have a signficant alpha value (which I would expect to be the case).
A beta of 0.61 wouldn't surprise me at all...
The 0.61 against the S&P500 was on daily movements over the last 12 months .... as was the 2.1 against the NZX50. Agree a lot of the annual increase was in a small number of days and this probably explains the lowish R squared factor.
Doesn't a beta >1 imply a positive correlation to the NZX50 and the returns will be higher than the market returns. In theory a beta of 2 for PEB implies a return of 2 times the market returns (for the last 12 months a lot more than twice and again because the increases came on a few days)
Winner, do note that Yahoo data is known to be corrupt for the NZ50, I calculate an NZ50 Beta of 1.45 for PEB from other data sources. But yes a positive correlation with the local market as one would intuitively anticipate, and a much lower correlation 0.61 with S&P500 volitility.
Of course our local market, the NZ50, is also not as volitile as the S&P500, the NZ50 Beta correlation with the S&P500 is 0.35
So, as a reality check 1.45 x 0.35 = 0.51, yeah so thereabouts the same magnitude of correlation 0.61
Is a daily Beta vs the S&P out by one day given NZ is ahead of the US, yet follows the US market - that is an up day in the US would result in an up day inNZ the following day.
Beta is volitility, not return, so a 2 means twice as volatile, though I guess if the market is going up, then that is a good thing?
Yes, you have to apply a one day shift for an S&P500 correlation else you will get values that are lower than reality would reflect.
Beta is not volatility
Beta is the expected change in Y given a change in x
Volatility is the variability in returns.
I would personally reccomend using a weekly Beta if you are trying to compare returns in different countries or where the trading times do not coincide.
Weekly Beta of NZSE all vs SPX Index is only 0.216 for last 4 years.
Hope that helps!
156 1,221,130 15:20 SP
Anyone care to guess what / who this is?
Thanks all.
Superlife sure do like the story.
http://www.superlife.co.nz/data_files/Gemino.pdf
http://www.superlife.co.nz/data_files/NZ_shares.pdf
that seems like an extraordinary weighting in one share for Superlife, surely unwise
Is it a coincident but Cellmid (CDY.ASX) is working on colorectal cancer screening tool, which one of PEB's products is CXCOLORECTAL? Are they licensing more from Cellmid or just coincident that they happen to be doing similar stuff.
"Cellmid is also working on Abcodia, a novel colorectal cancer screening tool, and its anti-midkine antibodies for cancer treatment have shown a reduction tumour growth and metastasis in animal models."
http://www.proactiveinvestors.co.uk/companies/news/66283/cellmid-books-half-year-net-profit-revenue-soars-492-66283.html
Also great profit for Cellmid given what they do its quite nice to see a company within the industry profit while still doing such extensive research and development.
Thanks Hancock’s, so just to clarify, Cxcolorectal is more of a prognostic tool than a detection prospect like the one Cellmid may be tweaking around with ?.
“Cxcolorectal is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer. The test predicts the aggressiveness of the tumour, allowing physicians to make the best decision regarding treatment for the patient. The gene signature passed a clinical study in Europe and Pacific Edge is currently refining Cxcolorectal to reduce cost and increase ease of delivery of the service. Cxcolorectal (Prognosis Gen I) has completed clinical trials and is preparing for commercial launch.”
http://www.pacificedge.co.nz/products/pipeline/
Next week we have the probable NZ50 listing, a feel good news story and a point of success in itself for any company, but more significantly the week after there is the USANZ conference in Brisbane, the SESAUA conference in Florida, and the OUSASM conference in Ohio, busy, busy
The USANZ conference in Brisbane is the one that PEB have told us they will present and publish the DHB user study results. I wouldn’t be surprised too if the USANZ (16-19th March) becomes a platform for a new product launch. The 2013 capital raising presentation advised that Cxbladder(triage) is due to be commercially available in Q2 2014 and the timing is about right for an announcement.
If anyone is going to the USANZ perhaps you could post some highlights ?
Ahem, should anyone of the good folk at PEB happen to read this thread, some information on Cxbladder(triage) would be most appreciated by many in helping the market to better understand it upon launch, the anticipated sales target goal, US and local price points, and market differentiation from Cxbladder(detect), many thanks.
http://www.pacificedgedx.com/news-an...n-new-zealand/
With posts like yours(and others) MAC who needs to go any where else. Thanks
this is an 8 minute slot on Tuesday 18th MarchQuote:
Validation of a urinary microRNA signature reveals high sensitivity for non-invasive detection of bladder urothelial carcinoma in patients undergoing surveillance - Nikhil Sapre
MAC, is this the presentation they are making? I cannot see anything else of relevance, but then, I'm a wee bit inexperienced in these matters
perhaps peb (the ST member) might be able to provide guidance? Please...
Hi Xerof, Pacific Edge have been silver sponsors of New Zealand USANZ branch conferences in the past, most recently in November, it’s possible they will do the same in Brisbane. I’m not sure of the timing of the presentation, I’ll drop a note to USANZ and ask.
http://www.cxbladder.com/for-healthc...-publications/
Yes, Magoo, you have nicely joined the dots
well done and thanks
This sort of picture of "revealed bids and offers" is not unusual for PEB - at least over the last couple of years I have been watching - and it has not generally correlated with a drop in price. My observation is that current depth is not a useful guide to future price movement for this particular stock.
The simple reality that the top twenty have not lowered their holdings to routinely maintain diversification limits, beyond shedding the dilution, says a lot about their confidence in where Pacific Edge is heading.
I was head of the Tiger Traders Technical Team who created the
Tiger
Traders
Technical
Team:
Tweeter -
Technical
Trader
Type
or T8 as it was affectionately known. (The next version was recoded in 3 days but it took us 4 months to come up with a name and eventually we settled on 'Bob' (Binary autOnomous Bulls***er)
Written entirely in BF 'he' was the basis for the bots that most celebrities use to run their twitter accounts.
You appear to based on a pirated version of our very successful 'Paris Hilton' derivation of the T8.
Best Wishes
Paper Tiger
It's so top secret that Google has purged it from search results, pending a Google Robotics acquisition of surfersteves IP.
Maybe Surfer Steve is a robot... probably the product one of Google's simulated annealing algorithms gone wrong. I think he's trapped in a pseudo-quantum dimension and sharetrader is his only bridge to reality.
I think what Steve is trying to say is that Xero's software is nothing special and the functionality that it contains could be easily reproduced.
PEB on the other hand has unique intellectual property, which cannot easily be reproduced.
Apparently there are automated ("robotic") software code generators, ie, software or algorithms that can automatically generate the computer code underlying a piece of desired software. Steve seems to think that these automated code generators could be used to replicate Xero's software, without needing any sort of 'bespoke' coding by a human software programmer.
That's my crude translation of his text and it could be completely wrong! :p
If steve really is as big a genius as he believes he is, his posts illustrate the biggest problem with many high level geeks: They have absolutely no idea how to communicate effectively.
The Huljich investment has dipped below the 5% SSH threshold it appears.
Given the numbers and the assumption that the rights were taken up in full then about 1M75 shares were disposed of between mid Oct and mid Feb but they still have over 14M left.
Meanwhile it would seem that the no news decline is now on.
Best Wishes
Paper Tiger
Dont think it means a lot, if you look at the numbers they actually have nearly 200000 more after the disclosure.
I would suggest they were just selling down to pay for the rights. We await developments,- inclusion in the nzx50, medicare progress update, full year update and report, sales report. Going to be an interesting couple of months. Any kind of affirmation of sales gaining a foothold should give the SP a good boot along.
:)
A bit of interesting related stuff regarding one of the PEB markers.
CELLMID ANNOUNCES THAT BRITISH JOURNAL OF PHARMACOLOGY FEATURES MIDKINE, A NOVEL ONCOLOGY ...
http://www.b3cnewswire.com/images/cl...llmid_logo.gif
- British Journal of Pharmacology features midkine in a special edition with 16 new publications
- Strong validation of midkine and its role in disease
Sydney, Australia, 6 March 2014 / B3C newswire / - Cellmid Limited (ASX: CDY) advises that The British Journal of Pharmacology (BJP) has recently published a special edition dedicated tomidkine (MK) including 16 research papers by various authors. The BJP is the premier peer-reviewed publication of the British Pharmacological Society, and it is recognised as one of the most influential international journals covering all aspects of experimental pharmacology.
The BJP Midkine Issue contains invited reviews from pre-eminent MK researchers from around the world, with comprehensive up-to-date articles covering the gamut of MK biology. Publications examine the role of MK in diseases including various cancers, kidney diseases, cardiovascular disease, multiple sclerosis and neurodegenerative disorders. New understanding of MK signaling and receptors is also featured. The full table of contents and the articles themselves can be viewed at
http://onlinelibrary.wiley.com/doi/1...sue-4/issuetoc.
“Being featured in a high-impact, internationally regarded journal with a global audience is a strong validation of MK’s importance in health and disease”, said Cellmid CEO, Maria Halasz. “Cellmid recognised this potential early on, and it is pleasing to see the increasing and ever wider realisation of MK’s potential utility as a disease target or as a therapeutic agent in its own right.”
“Having MK reviewed in this way is very helpful to Cellmid’s product development programs”, added Darren Jones, Head of Product Development. “Publications such as these provide strong supporting evidence to regulators, key opinion leaders and potential biotech and pharma partners. They provide a solid foundation upon which Cellmid can build its clinical programs and collaborations.”
Since its discovery in 1988, MK has been the subject of over 670 peer-review papers.
About Cellmid Limited (ASX: CDY) Cellmid is an Australian biotechnology company with lead drug candidates in immunooncology. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications, in particular solid tumours. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel oncology target midkine and midkine antagonists globally. The Company’s most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer.
About Midkine (MK)Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only present in a disease context, and targeting midkine is not expected to harm normal healthy tissues.
Contact: Maria Halasz, CEO T +612 9221 6830 Twitter: @mariahalasz
http://www.einnews.com/images/blank....wire&ref=-bots
Surfer and klingons,
Feel free to take this discussion to off market - you are cluttering this thread with irrrelevant crap - again
Absolutely agree Xerof, sick to death of the dribble. Suggest he starts a thread titled Quark - which is apparently 'an elementary particle and a fundamental constituent of matter'. It sounds like “kwork” and got its spelling from a whimsical poem in James Joyce’s Finnegans Wake. Nuff said?
Of course, a thread with this title would obviously be open to being filled with much elementary crap, and could well serve to be "found an uncomplicated solution to the problem".
As wiki puts it: el·e·men·ta·ry (ĕl′ə-mĕn′tə-rē, -trē)
adj.
1. Of, relating to, or constituting the basic, essential, or fundamental part
and from the Merriam-Webster dictionary, I quite like the example of fundamental: We need to address these problems on a more fundamental level. Just not on the PEB thread!
Please forgive, couldn't help myself!
Thank you for your in depth analysis copper, any 5 year old kid can see the sp has been going down. So?
See your post. I was answering another poster and trying to relate the share price etc to what was on this site. It's a sharechat site and not an extension of the Otago medical school blog site and all the crap of trying to be more knowledgeable than the other bloke.I am glad you are over 5 years and understand but to some posters the medical side is brilliant when answering a medical question related to PEB and how it may affect the share price but some of the other stuff is irrevelant as my post inferred .Hope that clears something.The share price still looks to me to be under a drifting trend and nothing seems to be in the wind to stop the drift.Nothing wrong with the Company it's just a lethargic market thing. Cheers..
Most investors dedicate an appropriate amount of time to research a company, its fundamental business model, its management, prospects for prosperity, and then decide what percentage of their hard earned savings from a humble salaried life to diversify and to invest for their future.
It takes a well informed and cognisant decision to successfully buy into a business, whether it’s listed in the share market or whether it is not.
They watch and learn about the business and market as much as they possibly can so as to manage risk through a better understanding and to affirm their investment decision as the months and years go by.
The more medical blogs as you put them the better, information and knowledge will reward you, on the contrary, many or most really don’t give a rat’s about short term moves in the share price over days or weeks.
I sincerely wish you luck Copper as I feel you may well need it.